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Hospital acquired pneumonia (HAP) is defined as an in-
flammatory process in lung tissue caused by infectious patho-
gens that is not present at the time of hospital admission and 
occurring 48 hours or more post admission1.
It represents the second most prevalent hospital-acquired 
infection2, and is an important concern for national public 
health system due to its high morbidity and mortality as well 
as the huge amount of health resources that consumes. It is 
important to note the differences between HAP and ventila-
tor-associated pneumonia (VAP). VAP is defined as the pneu-
monia that arises more than 48 to 72 hours after endotracheal 
intubation. Despite this infection is also a nosocomial pneu-
monia, in the next lines we will refer to HAP exclusively in pa-
tients without intubation.
There are different challenges for physicians in the treat-
ment of HAP. There is very little current information regard-
ing the aetiology of HAP. Most data concerning the aetiology 
of nosocomial pneumonia refer especially to VAP population. 
A recent review published by our group describes that up to 
60% of the cases of HAP are caused by gram-negative bacil-
li. Pseudomonas aeruginosa (24%) and Klebsiella spp. (11%) 
were the most frequently microorganisms isolated. The most 
frequent gram-positive pathogen associated with HAP was 
Staphylococcus aureus, accounting for 30% of the cases1. Re-
markably, the risk factors for multidrug resistant HAP are not 
well defined. Antibiotic resistance is a global health problem 
worldwide, especially in those infections caused by gram-neg-
ative bacilli. The infections caused by these multidrug resistant 
strains receive often inappropriate antimicrobial therapy and it 
might negatively impact on outcomes.  
New clinical practice guidelines for the management of 
adults with hospital-acquired pneumonia have been published 
in 2016 by the Infectious Diseases Society of America (IDSA) 
and American Thoracic Society (ATS)3. In these guidelines, the 
distinction between “early onset” pneumonia (occurs in the first 
96 hours of hospital admission) and “late onset” pneumonia 
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RESUMEN
La neumonía nosocomial es una causa frecuente de in-
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estos pacientes.
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the empirical antibiotic therapy for patients with HAP: risk of 
MDR infection and severity of disease. After the review of sev-
eral articles, the authors identify the use of prior intravenous 
antibiotic treatment within 90 days as the only risk factor for 
MDR HAP.  Other factors such as the existence of comorbid-
ity, recent hospital admission, the use of prior oral antibiot-
ics, current hospitalization in an area of high prevalence of 
multi-drug resistances or previous colonization by multi-drug 
resistant microorganisms were not taken into account. Those 
patients who require mechanical ventilation or present shock 
at the time of diagnosis were categorized as patients who had 
high risk of mortality. Some measures such as empirical double 
(appears after >96 hours) has been removed. This division was 
based on the fact that within the first days of hospital admission, 
gram-positive cocci still predominate on the flora of the respira-
tory system. After 5-7 days of illness, oropharynx fibronectin 
disappears and some receptors that allow the gram-negative 
rods colonization are exposed. Antibiotic pressure selects mul-
tiresistant strains and P. aeruginosa colonization4. Recent stud-
ies have questioned the relationship between the timing of no-
socomial pneumonia and the risk of multidrug-resistant (MDR) 
pathogens. However, most of these researches were focused on 
VAP5,6. 
The 2016 guidelines on HAP3 remark two factors to decide 
Not at high risk of mortality and no factors 
increasing the likelihood of MRSA
Not at high risk of mortality but with factors increasing the 
likelihood of MRSA
High risk of mortality or receipt of intravenous antibiotics 
during the prior 90 days
One of the following: One of the following: Two of the following, avoid 2 β-lactams:
Piperacilin-tazobactam 4.5 g IV q6h Piperacilin-tazobactam 4.5 g IV q6h Piperacilin-tazobactam 4.5 g IV q6h
OR OR OR
Cefepime 2 g IV q8h Cefepime or ceftazidime 2 g IV q8h Cefepime or ceftazidime 2 g IV q8h
OR OR OR 
Levofloxacin 750 mg IV daily Levofloxacin 750 mg IV daily
Ciprofloxacin 400 mg IV q8h
Levofloxacin 750 mg IV daily
Ciprofloxacin 400 mg IV q8h
OR OR
Imipenem 500 mg IV q6h
Meropenem 1 g IV q8h
Imipenem 500 mg IV q6h
Meropenem 1 g IV q8h
Imipenem 500 mg IV q6h
Meropenem 1 g IV q8h
OR OR
Aztreonam 2 g IV q8h Amikacin 15-20 mg/kg IV daily
Gentamicin 5-7 mg/kg IV daily
Tobramycin 5-7 mg/kg IV daily
OR
Aztreonam 2 g IV q8h
Plus:
Vancomycin 15 mg/kg IV q8-12h with goal to target 15-20 
mg/mL trough level (consider a loading dose of 25-30 mg/kg 
x 1 for severe illness
Plus:
Vancomycin 15 mg/kg IV q8-12h with goal to target 15-20 
mg/mL trough level (consider a loading dose of 25-30 mg/kg 
x 1 for severe illness
OR OR
Linezolid 600 mg IV q12h Linezolid 600 mg IV q12h
If MRSA coverage is not going to be used, include coverage 
for MSSA. 
Options include:
Piperacilin-tazobactam, cefepime, levofloxacin, imipenem, 
meropenem. Oxacilin, nafcillin, and cefazolin are preferred 
for the treatment of proven MSSA, but would ordinarily not 
be used in an empiric regimen for HAP.
If patient has severe penicillin allergy and aztreonam is going to be used instead of any β-lactam-based antibiotic, include coverage for MSSA.
Table 1  Recommended initial empiric antibiotic therapy for hospital-acquired pneumonia  
(non-ventilator-associated pneumonia) (adapted from reference 3)
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against gram-positive pathogens. It binds to different PBP, in-
cluding PBP2a, making it active against methicillin-resistant S. 
aureus (MRSA). It is one of the antibiotics with greater bacteri-
cidal effect against gram-positive and has an inmunomodula-
tory activity by inhibiting some toxins. As most beta-lactams, it 
does not have major side effects.
Tedizolid is an oxazolidinone with a long half-life and few 
significant side effects. A double-blind randomized clinical trial 
is currently underway to compare tedizolid versus linezolid in 
patients with HAP9.
Finally, dalbavancin is a recently approved glycopeptide 
used to treat infections caused by S. aureus and MRSA. Its 
main advantage is its dosage (once a week) and its few side ef-
fects10. Further information is needed to recommend this drug 
in patients with HAP.
In conclusion, HAP is a serious and difficult to treat illness. 
Some new therapeutic options that might improve the treat-
ment and prognosis of patients who develop this infection 
have recently appeared. Further studies are needed to define 
high risk patients for MDR-HAP and to check if new antibiotics 
have any impact to improve outcomes.
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coverage treatment for gram-negative bacilli are recommend-
ed only for these patients.
Empirical antibiotic treatments recommended by new 
guidelines for the different patient subgroups with HAP are 
shown in the table 1.
We have some concerns about these recommendations. 
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